|Recombinant Human IL-18BP Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Thr31-Gly194.
|Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.
|The protein has a predicted MW of 44.4 kDa. Due to glycosylation, the protein migrates to 60-80 kDa based on Tris-Bis PAGE result.
|Immobilized Human IL-18 at 5ug/ml (100ul/Well) on the plate. Dose response curve for Human IL-18BP, hFc Tag with the EC50 of 16.9ng/ml determined by ELISA (QC Test). The affinity constant of 0.04nM as determined in SPR assay (Biacore T200). See testing image for detail.
|> 95% as determined by Tris-Bis PAGE
|Less than 1EU per ug by the LAL method.
|Shipped at ambient temperature.
|Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
|Centrifuge the tube before opening. Reconstituting to a concentration more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water.
|Stability And Storage
|Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.